Histone post-translational modifications by HPLC-ESI-MS after HT29 cell treatment with histone deacetylase inhibitors

Area of Science:

• Molecular Biology
• Cancer Research
• Epigenetics

Background:

• Histone deacetylase inhibitors (HDACi) are a class of drugs with therapeutic potential in cancer.
• Understanding the specific effects of selective HDACi on histone modifications and cell cycle is crucial for drug development.
• HT29 colon cancer cells provide a model system to investigate HDACi mechanisms.

Purpose of the Study:

• To correlate histone post-translational modifications with cellular effects of HDAC inhibitors in HT29 colon cancer cells.
• To elucidate the mechanism of action of selective and non-selective HDAC inhibitors.
• To compare the potency and toxicity of different HDAC inhibitors.

Main Methods:

• Treatment of HT29 colon cancer cells with class I-selective (MS-275, MC1855), class II-selective (MC1568), and non-selective (SAHA) HDAC inhibitors.
• Liquid chromatography coupled with mass spectrometry (LC-MS) to analyze time- and concentration-dependent histone modifications.
• Assessment of cell cycle effects and cell death following HDAC inhibitor treatment.

Main Results:

• Different HDAC inhibitors induced distinct patterns of histone hyperacetylation and cell cycle arrest.
• Non-selective SAHA caused broad histone hyperacetylation and significant cell death.
• Class I-selective MC1855 was more potent and less toxic than SAHA, causing G2/M arrest.
• Class I-selective MS-275 showed specific H4 hyperacetylation and G0/G1 arrest.
• Class II-selective MC1568 induced minimal H4 hyperacetylation with no cell cycle effect.

Conclusions:

• The degree of histone post-translational modifications correlates with the cellular effects of HDAC inhibitors.
• Selective HDAC inhibitors exhibit distinct mechanisms of action and toxicity profiles.
• These findings provide insights into the development of more potent and targeted HDAC inhibitors for colon cancer therapy.